Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.
Goff LW, Azad NS, Stein S, Whisenant JG, Koyama T, Vaishampayan U, Hochster H, Connolly R, Weise A, LoRusso PM, Salaria SN, El-Rifai W, Berlin JD.
Goff LW, et al.
Invest New Drugs. 2019 Apr;37(2):315-322. doi: 10.1007/s10637-018-0663-0. Epub 2018 Sep 6.
Invest New Drugs. 2019.
PMID: 30191522
Free PMC article.
Clinical Trial.
Standard 3 + 3 dose escalation was used, where the starting dose of alisertib was 10 mg twice daily (Days 1-3), with leucovorin (400 mg/m(2)) and oxaliplatin (85 mg/m(2)) on Day 2 followed by continuous 46-h 5-FU (2400 mg/m(2)) infusion on Days 2-4 in 14-day cycles. Fourte …
Standard 3 + 3 dose escalation was used, where the starting dose of alisertib was 10 mg twice daily (Days 1-3), with leucovorin (400 mg/m(2) …